Latest Insider Transactions at Poseida Therapeutics, Inc. (PSTX)
This section provides a real-time view of insider transactions for Poseida Therapeutics, Inc. (PSTX). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Poseida Therapeutics, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Poseida Therapeutics, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 08
2025
|
Malin Life Sciences Holdings LTD > 10% Shareholder |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
11,835,673
-100.0%
|
-
|
|
Jan 08
2025
|
Marcea Bland Lloyd |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
68,950
-100.0%
|
-
|
|
Jan 08
2025
|
John P. Schmid |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
58,950
-100.0%
|
-
|
|
Jan 08
2025
|
Luke Corning |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
58,950
-100.0%
|
-
|
|
Jan 08
2025
|
Rafael Amado |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
58,950
-100.0%
|
-
|
|
Jan 08
2025
|
Harry J Leonhardt GC & Chief Compliance Officer |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
223,640
-100.0%
|
-
|
|
Jan 08
2025
|
Syed Ali Aamir Rizvi Chief Medical Officer |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
185,000
-100.0%
|
-
|
|
Jan 08
2025
|
Johanna Mylet Chief Financial Officer |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
254,852
-100.0%
|
-
|
|
Jan 08
2025
|
Charles M Baum |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
78,600
-100.0%
|
-
|
|
Jan 08
2025
|
Cynthia Collins |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
58,950
-100.0%
|
-
|
|
Jan 08
2025
|
Kristin Yarema President and CEO |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
615,836
-100.0%
|
-
|
|
Jan 08
2025
|
Mark J Gergen President and CEO |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
636,726
-100.0%
|
-
|
|
Jan 02
2025
|
Mark J Gergen President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
23,313
-3.56%
|
$209,817
$9.6 P/Share
|
|
Dec 10
2024
|
Mark J Gergen President and CEO |
SELL
Open market or private sale
|
Direct |
30,000
-4.4%
|
$270,000
$9.46 P/Share
|
|
Dec 10
2024
|
Mark J Gergen President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
30,000
+4.22%
|
$60,000
$2.78 P/Share
|
|
Nov 26
2024
|
Mark J Gergen President and CEO |
SELL
Open market or private sale
|
Direct |
30,000
-4.4%
|
$270,000
$9.27 P/Share
|
|
Nov 26
2024
|
Mark J Gergen President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
30,000
+4.22%
|
$60,000
$2.78 P/Share
|
|
Jun 17
2024
|
Luke Corning |
BUY
Grant, award, or other acquisition
|
Direct |
19,650
+25.0%
|
-
|
|
Jun 17
2024
|
Marcea Bland Lloyd |
BUY
Grant, award, or other acquisition
|
Direct |
19,650
+22.18%
|
-
|
|
Jun 17
2024
|
John P. Schmid |
BUY
Grant, award, or other acquisition
|
Direct |
19,650
+25.0%
|
-
|
|
Jun 17
2024
|
Rafael Amado |
BUY
Grant, award, or other acquisition
|
Direct |
19,650
+25.0%
|
-
|
|
Jun 17
2024
|
Charles M Baum |
BUY
Grant, award, or other acquisition
|
Direct |
19,650
+20.0%
|
-
|
|
Jun 17
2024
|
Cynthia Collins |
BUY
Grant, award, or other acquisition
|
Direct |
19,650
+25.0%
|
-
|
|
Apr 01
2024
|
Syed Ali Aamir Rizvi Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
185,000
+50.0%
|
-
|
|
Mar 01
2024
|
Johanna Mylet Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
18,091
-6.84%
|
$72,364
$4.13 P/Share
|
|
Mar 01
2024
|
Johanna Mylet Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
80,743
+23.4%
|
-
|
|
Mar 01
2024
|
Brent Warner President, Gene Therapy |
SELL
Payment of exercise price or tax liability
|
Direct |
35,739
-7.86%
|
$142,956
$4.13 P/Share
|
|
Mar 01
2024
|
Brent Warner President, Gene Therapy |
BUY
Grant, award, or other acquisition
|
Direct |
80,743
+15.08%
|
-
|
|
Mar 01
2024
|
Harry J Leonhardt GC & Chief Compliance Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
16,306
-7.06%
|
$65,224
$4.13 P/Share
|
|
Mar 01
2024
|
Harry J Leonhardt GC & Chief Compliance Officer |
BUY
Grant, award, or other acquisition
|
Direct |
80,743
+25.91%
|
-
|
|
Mar 01
2024
|
Mark J Gergen President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
34,157
-4.98%
|
$136,628
$4.13 P/Share
|
|
Feb 01
2024
|
Mark J Gergen President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
47,162
-6.44%
|
$141,486
$3.41 P/Share
|
|
Jan 02
2024
|
Mark J Gergen President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
125,000
+14.58%
|
-
|
|
Jan 02
2024
|
Kristin Yarema President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
250,000
+29.18%
|
-
|
|
Jun 15
2023
|
Marcea Bland Lloyd |
BUY
Grant, award, or other acquisition
|
Direct |
19,650
+28.5%
|
-
|
|
Jun 15
2023
|
John P. Schmid |
BUY
Grant, award, or other acquisition
|
Direct |
19,650
+33.33%
|
-
|
|
Jun 15
2023
|
Cynthia Collins |
BUY
Grant, award, or other acquisition
|
Direct |
19,650
+33.33%
|
-
|
|
Jun 15
2023
|
Luke Corning |
BUY
Grant, award, or other acquisition
|
Direct |
19,650
+33.33%
|
-
|
|
Jun 15
2023
|
Charles M Baum |
BUY
Grant, award, or other acquisition
|
Direct |
19,650
+25.0%
|
-
|
|
May 01
2023
|
Rafael Amado |
BUY
Grant, award, or other acquisition
|
Direct |
39,300
+50.0%
|
-
|
|
Apr 11
2023
|
Kristin Yarema President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
356,836
+50.0%
|
-
|
|
Mar 01
2023
|
Brent Warner President, Gene Therapy |
SELL
Payment of exercise price or tax liability
|
Direct |
26,617
-6.64%
|
$133,085
$5.35 P/Share
|
|
Mar 01
2023
|
Brent Warner President, Gene Therapy |
BUY
Grant, award, or other acquisition
|
Direct |
92,772
+18.8%
|
-
|
|
Mar 01
2023
|
Harry J Leonhardt GC & Chief Compliance Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,323
-2.91%
|
$21,615
$5.35 P/Share
|
|
Mar 01
2023
|
Harry J Leonhardt GC & Chief Compliance Officer |
BUY
Grant, award, or other acquisition
|
Direct |
92,772
+38.45%
|
-
|
|
Mar 01
2023
|
Johanna Mylet Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,323
-2.38%
|
$21,615
$5.35 P/Share
|
|
Mar 01
2023
|
Johanna Mylet Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
92,772
+33.77%
|
-
|
|
Mar 01
2023
|
Mark J Gergen President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
269,586
+30.94%
|
-
|
|
Feb 01
2023
|
Mark J Gergen President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
31,819
-8.79%
|
$222,733
$7.0 P/Share
|
|
Feb 01
2023
|
Eric Ostertag Director |
SELL
Payment of exercise price or tax liability
|
Direct |
11,776
-1.4%
|
$82,432
$7.0 P/Share
|